There are currently 11 ongoing clinical trials involving Essential Tremor
Of the 11 trials,7 trials are in Phase II
Furthermore, 2 trials are in Phase I
The global pharmaceutical industry is steadily developing new drugs for Essential Tremor, a central nervous system condition. The largest number of ongoing clinical trials for Essential Tremor is conducted in North America. Europe and Asia-Pacific are among some of the other prominent regions engaged in Essential Tremor-related drug trials.
Praxis Precision Medicines Inc: The leading ongoing Essential Tremor related clinical trial sponsor
Praxis Precision Medicines Inc is the top sponsor for Essential Tremor-related ongoing clinical trials.
Huazhong Pharmaceutical Co Ltd, Western University, Lawson Health Research Institute, University Medical Centre Ljubljana, and Puretech Health Plc are among other notable clinical trial sponsors involved in Essential Tremor. A clinical trial sponsor can be a Company, Government, Individual, or Institution.
Marketed Drugs involving Essential Tremor
Arotinolol (Acemail, Arotinolol hydrochloride), Atenolol (Betacard), and Diazepam are key marketed drugs involving Essential Tremor.
Arotinolol (Acemail, Arotinolol hydrochloride) is an antihypertensive drug. It functions via Alpha 1 Adrenergic Receptor (ADRA1) Antagonist, Beta 1 Adrenergic Receptor Antagonist mechanism of action. It is formulated as sugar coated and film coated tablets for oral route of administration. Arotinolol indicated for the treatment of mild to moderate essential hypertension, angina, tachyarrhythmia, and essential tremor. Arotinolol was first approved in 1994 and is marketed in Japan by Sawai Pharmaceutical Co Ltd.
Atenolol (Betacard) is a phenol ether derivative acts as an antihypertensive agent. It functions via Beta 1 Adrenergic Receptor (Beta 1 Adrenoreceptor or ADRB1) Antagonist mechanism of action. It is formulated as tablets for oral route of administration. Betacard is indicated for the treatment of angina, myocardial infarction, arrhythmias, hypertension and migraine prophylaxis and also indicated for coronary heart disease, essential and senile tremor, agitation and tremor with withdrawal syndrome, sinus tachycardia, paroxysmal atrial tachycardia, supraventricular and ventricular premature beats, supraventricular and ventricular tachycardia, atrial tachyarrhythmia, atrial flutter. Atenolol was first approved in 1993 and is marketed in Germany, India, and Russia by Heumann Pharma GmbH & Co Generica KG.
United States of America
China
Switzerland
United States of America
United States of America
United States of America
United States of America
Germany
France
Switzerland
Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.
Access more premium companies when you subscribe to Explorer